Multiple Myeloma: Adding Daratumumab to Carfilzomib/Dexamethasone Enhances Efficacy

Results from the phase 3 CANDOR trial show that for relapsed/refractory multiple myeloma, adding daratumumab (D) to carfilzomib/dexamethasone (Kd) increases efficacy compared with Kd alone. "Lenalidomide and bortezomib frontline exposure has raised a growing need for novel treatments for patients with relapsed or refractory multiple myeloma," write the study investigators in their publication in The Lancet, led by Meletios Dimopoulos, MD, Professor and Chairman of Clinical Therapeutics at the Na...
Continue reading

Daratumumab and Hyaluronidase-fihj FDA Approved for Multiple Myeloma

Daratumumab and hyaluronidase-fihj (Darzalex Faspro™, Janssen Biotech, Inc.) has been approved by the FDA and allows for subcutaneous dosing of daratumumab for adult patients with newly diagnosed or relapsed/refractory multiple myeloma. Previously, intravenous daratumumab was approved for the following indications for patients with multiple myeloma: in combination with bortezomib, melphalan, and prednisone, in combination with lenalidomide and dexamethasone, in combination with bortezomib and de...
Continue reading

Adding Daratumumab to VMP for Transplant-Ineligible Myeloma: Maria Victoria Mateos, MD, PhD

Over half of patients with newly diagnosed multiple myeloma (NDMM) are ineligible for autologous stem cell transplantation. For these patients, a combination therapy consisting of the proteasome inhibitor bortezomib with melphalan and prednisone is one of the preferred treatments. Adding daratumumab to standard regimens for transplant-ineligible NDMM and relapsed/refractory multiple myeloma has had promising results. Now, data from the phase 3 ALCYONE trial show that adding daratumumab to bortez...
Continue reading

Daratumumab Increases Listeria Susceptibility

Patients with multiple myeloma who are receiving daratumumab (Darzalex®, Janssen) have an increased susceptibility to listeriosis, a potentially deadly infection by Listeria monocytogenes, a gram-positive bacterium to which individuals with weakened immune systems are susceptible. Daratumumab, a CD38 monoclonal antibody, is effective against multiple myeloma because CD38 is strongly expressed in multiple myeloma cells. However, activated macrophages also express CD38. It seems to be an important...
Continue reading

Transplant-Ineligible Myeloma: Adding Daratumumab to VMP Increases Survival

Adding daratumumab to bortezomib/melphalan/prednisone (VMP) increases overall survival in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), according to results of the phase 3 ALCYONE trial to be presented in December at the American Society of Hematology (ASH) Annual Meeting and Exposition. Patients who are ineligible for autologous stem cell transplantation comprise approximately half of NDMM patients, and the combination of bortezomib, a proteasome inhibitor, with m...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.